For the Quarter Ending June 2022
The Sulfadiazine market in North America remained stabilized in the second quarter of 2022, owing to steady downstream derivative offers throughout this period. As a result of China and Russia's limitations on upstream exports, demand from the end-user pharmaceutical sector remained stabilized, and market players maintained consistent offtakes in the regional market. Persistent demand for Antibacterial medications for the treatment of urinary tract infections is seen among the domestic buyers of the region. High inflation and crippled logistics availability made market players make consistent offtakes at slightly reduced margins in the market. In addition, superior healthcare infrastructure resources aided North American market expansion.
In the Asia-Pacific region, a surge in the market of Sulfadiazine API was witnessed during quarter 2 of 2022, backed by the steady demand from end-user pharmaceutical industries. Furthermore, crippled logistics and supply disruptions availability pushed Sulfadiazine's prices upwards. In addition, the increment in bacterial infections further added to the already extended offtake of the Sulfadiazine API market. Besides, in the second half of the second quarter, improvement in the production activities amid relaxation in the Chinese lockdown curbs gradually eased the prices of Sulfadiazine API in the domestic market. Meanwhile, currency depletion against the US dollar also contributed to a declination of the product costs in the APAC region.
European Sulfadiazine prices witnessed stability in the second quarter of 2022, backed by the hampered supply chain amidst the extended war between Russia & Ukraine coupled with steady demand fundamentals in this period. Furthermore, the Euro depletion against the US dollar amid high inflation conclusively affected the price momentum of Sulfadiazine in the European market. Consistency in demand for the product in the second quarter resulted from the growing incidence of urinary tract infections (UTI) among the elderly and driving the Sulfadiazine market forward. As a result of the supply limitations, some players predicted that the present trend would keep the Sulfadiazine market in Europe solid for the next quarter.
For the Quarter Ending March 2022
The Sulfadiazine market in North America remained consolidated in the first quarter of 2022, owing to robust downstream derivative offers throughout the period. As a result of China and Russia's limits on raw materials exports, demand from end-user pharmaceutical sector remained strong, maintaining positive views on the regional market. Antibacterial medications were in more demand as the frequency of urinary tract infections and toxoplasmosis gondii encephalopathy among HIV+ persons rose. North America led the sulfadiazine market because of the rising demand for wound care products in countries like the United States and Canada. In addition, superior healthcare infrastructure facilities in these nations aided North American market expansion.
In the Asia-Pacific region, an upsurge in the market of Sulfadiazine API was observed during the quarter 1 of 2022, backed by solid demand from end-user pharmaceutical industries. Furthermore, high fuel prices and freight charges pushed the prices of Sulfadiazine upwards. Later in the second half of the first quarter, surplus inventories of Sulfadiazine API in the domestic market as covid resurfaced in China which harmed the growth of the Sulfadiazine market. The enhanced burn injuries among the different populations were the prime factor that propelled the demand for Sulfadiazine. Besides, increased bacterial infections further added to the already augmented offtake of the Sulfadiazine API market.
Because of growing awareness of silver sulfadiazine derivatives in countries such as the UK and Germany due to its more successful outcomes than other antibiotics, the overall market of Sulfadiazine in Europe grew significantly in the first quarter of 2022. The supply chain was hampered due to the extended wars between Eastern European nations. Furthermore, the Sulfadiazine market in Belgium increased due to the growing incidence of urinary tract infections (UTI) among the elderly, propelling the Sulfadiazine market forward. As a result of the supply constraints, some industry players predicted that the present trend would keep the Sulfadiazine market in Europe solid until the next quarter.